Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →Save on this medicine
Same active ingredient — pay up to 33% less
These brands contain the same active ingredient (Sotorasib). Same strength and form. Confirm the switch with your doctor or pharmacist.
More from Sotoras
Other strengths and forms by Beacon Pharmaceuticals PLC
Indications & Uses
Sotoras is indicated for:
Pharmacology
Sotorasib is a potent and highly selective inhibitor of KRASG12C (Kirsten rat sarcoma viral oncogene homolog). It binds covalently and irreversibly to the unique cysteine of KRASG12C. Once KRASG12C is inactivated, tumour cell signalling and survival are blocked, cell growth is inhibited, and apoptosis is promoted, but only in tumours that carry KRASG12C. This mutation is an oncogenic driver of tumourigenesis across multiple cancer types. The binding is unique because it involves both the P2 pocket and the His95 surface groove, and this strengthens the potency and selectivity. It locks the protein in an inactive state, which prevents downstream signalling, and wild-type KRAS is not affected. In vitro and in vivo studies showed inhibition of KRASG12C with minimal detectable off-target activity against other cellular proteins and processes. In numerous pre-clinical models expressing KRASG12C, the medicine impaired oncogenic signalling and tumour cell survival at clinically relevant exposures. Sotorasib also increased antigen presentation and inflammatory cytokine production, and only in tumour cells with KRASG12C. It induced anti-tumour inflammatory responses and immunity, and this drove permanent and complete tumour regressions in immunocompetent mice implanted with tumours expressing KRASG12C.
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
The usual dose of Sotorasib is 960 mg once a day, taken as eight 120 mg tablets by mouth. You keep taking it until the disease gets worse or the side effects become unacceptable. Try to take Sotorasib at the same time each day. It can be taken with or without food.
Swallow the tablets whole. Don't chew, crush or split them.
If you miss a dose by more than 6 hours, skip it and take the next dose as prescribed the next day. Don't take 2 doses at the same time to make up for the missed one. If you vomit after taking Sotorasib, don't take an extra dose. Just take the next dose as prescribed the next day.
Side Effects
Two serious side effects have been reported with Sotorasib: hepatotoxicity (liver damage) and interstitial lung disease (ILD). Hepatotoxicity Twenty-five percent of trial participants had liver dysfunction. This showed up as raised hepatic transaminases, raised bilirubin and drug-induced hepatitis. Liver function tests should be done before Sotorasib is started, then every 3 weeks for the first 3 months, and once a month after that. The tests should include AST, ALT and bilirubin levels. Patients should be told to report signs of liver trouble to their oncology team, such as abdominal pain, jaundice, dark urine or itching. If a patient develops grade 2, 3 or 4 hepatotoxicity, Sotorasib should be held until the symptoms settle to grade 1 or better. It is then restarted at a lower dose. Interstitial Lung Disease ILD was rare, but several trial participants developed it. Patients should be checked regularly for breathing problems such as shortness of breath, cough and fever, and they should be encouraged to report these quickly to their medical team. If ILD is suspected, Sotorasib should be held while the patient is being worked up for these symptoms.
Cautions & Contraindications
Warnings & Precautions
Sotorasib can cause hepatotoxicity, which may lead to drug-induced liver injury and hepatitis. In CodeBreaK 100, 357 patients received Sotorasib. Hepatotoxicity occurred in 1.7% of them (all grades) and in 1.4% at Grade 3. Increased alanine aminotransferase (ALT)/increased aspartate aminotransferase (AST) was seen in 18% of patients, with 6% at Grade 3 and 0.6% at Grade 4. The median time to first onset of increased ALT/AST was 9 weeks (range: 0.3 to 42). In 7% of patients, increased ALT/AST led to dose interruption or reduction, and in 2.0% Sotorasib was discontinued because of it. Along with dose interruption or reduction, 5% of patients received corticosteroids to treat hepatotoxicity. Monitor liver function tests (ALT, AST and total bilirubin) before starting Sotorasib, every 3 weeks for the first 3 months of treatment, then once a month or as clinically indicated. Test more often in patients who develop transaminase and/or bilirubin elevations. Withhold Sotorasib, reduce the dose or stop it permanently, depending on how severe the adverse reaction is. Interstitial Lung Disease (ILD)/Pneumonitis: Sotorasib can cause ILD/pneumonitis, and it can be fatal. Among the 357 patients who received Sotorasib in CodeBreaK 100, ILD/pneumonitis occurred in 0.8%. All of these cases were Grade 3 or 4 at onset, and 1 case was fatal. The median time to first onset was 2 weeks (range: 2 to 18 weeks). Sotorasib was discontinued because of ILD/pneumonitis in 0.6% of patients. Monitor patients for new or worsening lung symptoms that point to ILD/pneumonitis (e.g., dyspnea, cough, fever). If ILD/pneumonitis is suspected, withhold Sotorasib immediately, and stop it permanently if no other potential cause of ILD/pneumonitis is found.
Pregnancy & Breastfeeding
Pregnancy: There are no data on the use of Sotorasib in pregnant women. Studies in animals have shown reproductive toxicity. Patients must be told about the possible hazards to the foetus if Sotorasib is used during pregnancy, or if the patient becomes pregnant while she is taking it.
Breast-feeding: We don't know if Sotorasib or its metabolites pass into human milk, so a risk to newborns and infants can't be excluded. A decision must be made either to stop breast-feeding or to stop or abstain from Sotorasib therapy. This decision should take into account the benefit of breast-feeding for the child and the benefit of the therapy for the woman.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
Overdose
No one has reported an overdose of Sotoras so far, so there is no clinical experience to draw on. If an overdose does happen, the patient should be treated for the symptoms they show, and supportive care given as needed.
⚠️ In an emergency call 999 or go to the nearest hospital emergency department.
Storage
Keep Sotorasib below 25°C, in a cool and dry place. Protect it from light. Make sure children can't reach it.
Drug Interactions
Common questions about Sotoras 120 mg
What is Sotoras 120 mg Tablet?
Sotoras 120 mg Tablet is a medicine that contains Sotorasib. It is made by Beacon Pharmaceuticals PLC. It belongs to the Cytotoxic Chemotherapy group of medicines.
What is Sotoras used for?
Sotoras is used for: Cancer.
What are the side effects of Sotoras?
Two serious side effects have been reported with Sotorasib: hepatotoxicity (liver damage) and interstitial lung disease (ILD). Hepatotoxicity Twenty-five percent of trial participants had liver dysfunction.
Can I take Sotoras during pregnancy or while breastfeeding?
Pregnancy: There are no data on the use of Sotorasib in pregnant women. Studies in animals have shown reproductive toxicity. Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
What happens if I take too much Sotoras?
No one has reported an overdose of Sotoras so far, so there is no clinical experience to draw on. If an overdose does happen, the patient should be treated for the symptoms they show, and supportive care given as needed. In an emergency call 999 or go to the nearest hospital emergency department.
How should I store Sotoras?
Keep Sotorasib below 25°C, in a cool and dry place. Protect it from light.
Can I take other medicines with Sotoras?
Some medicines can interact with Sotorasib, for example: Digoxin. Tell your doctor or pharmacist about every medicine you take.
Is there a cheaper medicine with the same ingredient?
Sotoxen by Everest Pharmaceuticals Ltd. has the same ingredient and strength for ৳1,000.00 per unit, compared with ৳1,500.00 for Sotoras. Ask your doctor or pharmacist before switching.
Do I need a prescription for Sotoras?
Sotoras is a prescription (Rx) medicine. Take it as your doctor advises.